- Earth
Science Tech has launched a new sales division focused on CBD, led by
Industry-veteran Erika Franck
- ETST’s
portfolio is positioned in the dually lucrative biotechnology and
cannabis/cannabidiol industries
- Biotechnology
currently represents the largest segment of the growing legal cannabis
market
Earth Science Tech Inc. (OTCQB: ETST) recently
launched a new sales unit to further strengthen its position in the CBD
marketplace for medical and pharmaceutical products. Erika Franck, who has
previously served as the company’s clinical and therapeutics sales director,
will be heading the division. ETST made this move in accordance with the
growing use of CBD in the licensed medical fields and alternate medicinal
streams.
The company, under the leadership of Franck, will target
medical experts and specialists, suppliers, acupuncturists, chiropractors,
practitioners of holistic wellness and alternative therapies, and
veterinarians. With the appointment of Franck, the company receives her sound
knowledge and experience in the pharmaceutical and orthopedics industry.
“I am thrilled to be part of this amazing team and to have
the opportunity to apply my expertise in spearheading this new clinical
division for ETST,” Franck stated in a news release (http://ibn.fm/Q84nZ). “Our
shared vision is to improve patients’ quality of life, and I am honored to
participate in ETST’s continued growth as we achieve this mission.”
Earth Science Tech is well-positioned as a biotechnology
company which focuses on the research and development of CBD, pharmaceuticals
and medical device products. The company’s pure CBD oil is manufactured using
CO2 liquid extraction processes; ETST prides itself on offering the finest
quality pure CBD oil on the market.
The biotechnology segment of the cannabis industry consists
of pharmaceutical firms focused on the research and development behind new
drugs and products that utilize cannabinoids, which are the active compounds
within cannabis. Currently the largest sector in the legal cannabis market, it
is expected to see further growth as more entities around the world continue
researching cannabinoids (http://ibn.fm/icNh9).
This trend is encouraging for biotechnology companies like Florida-based ETST.
ETST projects a robust portfolio through its two wholly
owned subsidiaries, which are focused on the research and production of
cutting-edge industrial hemp and cannabis/cannabidiol (CBD) products to take
advantage of the potential seen in the burgeoining cannabis industry.
ETST subsidiary Earth Science Pharma Inc. is engaged in the
production of noninvasive economical diagnostic testing tools, medical devices
and vaccines for sexually transmitted infections and/or diseases. Their first
STI home detection kit using a modified panty liner (MSN-2), named Hygee, is a
revolutionary product that can be used for chlamydia testing by women from
their homes. The MSN-2 technology is further being utilized to screen for other
STIs such as gonorrhea and thichomoniasis, and it holds disruptive
potential in the women’s health sector.
Cannabis Therapeutics Inc., another of ETST’s subsidiaries,
was formed as an emerging biotechnology company poised to become a world leader
in cannabinoid research and development for a broad line of
cannabis/cannabinoid-based pharmaceuticals, nutraceuticals and other products
and solutions.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates
relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
